GT-316

N/A

Report date: 2026/04/30 20:00:20

Base Information

Drug NameGT-316
Drug Alias NameGT316
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsDigestive System Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator Companiesshenzhen Grit Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active Companiesshenzhen Grit Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsOvarian NeoplasmsDigestive System Neoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A